AGTC Announces Agenda for R&D Day on January 28, 2020, in New York (EIN News Desk)

AGTC Announces Agenda for R&D Day on January 28, 2020 in New York

UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it will host an R&D Day beginning at 7:30 am ET on Tuesday, January 28, 2020, in New York.

AGTC’s R&D Day will include a review of the recently reported positive interim data from the company’s ongoing Phase 1/2 clinical trial in X-linked retinitis pigmentosa (XLRP) as well as data from the ongoing Phase 1/2 clinical trials in achromatopsia (ACHM), which the company expects to report later this month. The event will also include a review of the company’s manufacturing capabilities and pre-clinical programs and will feature discussions with management, patients and key opinion leaders.

Learn more about AGTC Announces Agenda for R&D Day on January 28, 2020, in New York.

Related news:

AGTC Reports Positive Six-Month Data From Its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa.

AGTC Completes Enrollment of Third Group in the Dose Escalation Portion of the Achromatopsia CNGA3 Phase 1/2 Clinical Study.
X